Page last updated: 2024-11-04

vorinostat and Non-alcoholic Fatty Liver Disease

vorinostat has been researched along with Non-alcoholic Fatty Liver Disease in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.

Research Excerpts

ExcerptRelevanceReference
"Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide."1.51Gene expression profile-based drug screen identifies SAHA as a novel treatment for NAFLD. ( Chen, S; Cheng, J; Cheng, Z; Deng, L; Liang, B; Liu, Y; Tang, X; Wang, Z; Wen, Y; Xin, H, 2019)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cheng, Z1
Wen, Y1
Liang, B1
Chen, S1
Liu, Y1
Wang, Z1
Cheng, J1
Tang, X1
Xin, H1
Deng, L1

Other Studies

1 other study available for vorinostat and Non-alcoholic Fatty Liver Disease

ArticleYear
Gene expression profile-based drug screen identifies SAHA as a novel treatment for NAFLD.
    Molecular omics, 2019, 02-11, Volume: 15, Issue:1

    Topics: Diacylglycerol O-Acyltransferase; Drug Evaluation, Preclinical; Gene Expression Profiling; Hep G2 Ce

2019